Source: CureToday articles
Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer.
Recent Content
- Clinical Trials Enhance Care for Advanced Gastrointestinal Cancers
- Analysis Reveals Polypharmacy Challenges in Patients With Cancer
- Trastuzumab Deruxtecan Plus Pertuzumab Improves Progression-Free Survival in Patients With HER2+ Metastatic Breast Cancer
- Enhertu Combo Improves Progression in HER2+ Metastatic Breast Cancer
- My 11-Year Metastatic Breast Cancer Story Defied the Standard Path
- A Step Forward: Optimizing the Delivery of Pegaspargase Therapy in Adult Patients With ALL
- Migraine With Aura Plays Most Prominent Role in Women With Young-Onset CIS
- Antibiotic Use in Infants and Young Children May Increase Risk of Allergic Conditions
- Training and Education Ensure Safe Handling of Hazardous Drugs
- NCPA Report Outlines Potential Negative Impacts of MDPNP, Solutions